ALLO

Allogene Therapeutics, Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001737287 Biotech & Drug Discovery

$1.21 −0.04 (−3.20%)

Oct 26 4:00 PM ET · prev $1.25

Market cap

$431.9M

Small cap

Consensus

Buy

89% Buy or better · 18 analysts

Median target

$9.00

+644% · range $4.00–14.00

Next earnings

Oct 29

in 2 days · EPS est. −$0.14

1 year

−1.6%

from $1.23 · Oct 27

30 days

−25.8%

from $1.63

52-week range

$1.05–3.06

−60% from high · low Nov 6

Avg volume 20D

6.19M

shares / day

Short interest

🔒 Subscribers only

Insider net

−$626.9K

0 buyers · 6 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 5 reports · 90 days

Balance 1 bearish · 1 bullish · 3 neutral oldest → newest, height = score

Avg score

·High conf. 4/5 ·Next Earnings date, Oct 29, 2026

Strongest NEUTRAL Geoffrey M. Parker, an officer of Allogene Therapeutics, filed a Form 144 notice of intent to sell 100,000…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Mar 2 1 insider sell $18.5K at $2.60
S Mar 16 2 insiders sell $129.9K at $2.47
S Mar 31 1 insider sell $7.2K at $2.50
E Apr 21 FDA: Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial…
S Apr 21 1 insider sell $22.1K at $2.31
R Jun 22 Allogene Therapeutics filed a 424B5 prospectus supplement for an at-…
S Aug 21 1 insider sell $63.0K at $2.12
S Oct 21 1 insider sell $48.7K at $1.34

Signal stack

Where each data set points today.

InsidersBEARISH

6 insiders sold $626.9K.
InstitutionsBULLISH

Q2 2026: 63 added (0 new), 11 trimmed or exited.
AnalystsBULLISH

16 of 18 rate it Buy or better. Every target is above the price.
EstimatesFLAT

Current-quarter EPS estimate −$0.142 → −$0.141 over 90 days. 2 up, 1 down in 30 days.
TrendDOWNTREND

28% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	ADD	30,146,963	$62.7M
STATE STREET CORP	DOUBLED	19,025,826	$39.6M
PRIMECAP MANAGEMENT CO/CA/	ADD	13,123,440	$27.3M
VANGUARD CAPITAL MANAGEMENT LLC	ADD	12,166,636	$25.3M
FMR LLC	DOUBLED	12,009,043	$25.0M
CITADEL ADVISORS LLC	ADD	10,087,770	$21.0M
GEODE CAPITAL MANAGEMENT, LLC	ADD	7,049,328	$14.7M
GOLDMAN SACHS GROUP INC	DOUBLED	6,148,959	$12.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts

Buy 89% rate it Buy or better

Strong Buy6Buy10Hold2Sell0Strong Sell0

12-month targets · 9 analysts

$1.21 $4.00 $9.00 $14.00

Price is below the lowest target. Median implies +644%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 17, 2026	Citizens REITERATE	REITERATE	Market Outperform

Insider ledger

Form 4

bought · 0 insiders

$626.9K

sold · 6 insiders

Date	Insider	Type	Value
Oct 21, 2026	Parker Geoffrey M. CHIEF FINANCIAL OFFICER	SELL	$48.7K
Aug 21, 2026	Douglas Earl Martin SVP, General Counsel	SELL	$63.0K
Jul 1, 2026	Roberts Zachary President and CEO	AWARD	134,530 sh
Jul 1, 2026	Roberts Zachary President and CEO	AWARD	476,190 sh
Jun 18, 2026	WITTE OWEN N. Director	AWARD	95,400 sh
Jun 18, 2026	Barrett Elizabeth A. Director	AWARD	95,400 sh
Jun 18, 2026	Humer Franz B Director	AWARD	95,400 sh
Jun 18, 2026	Kazam Joshua A Director	AWARD	95,400 sh

Earnings setup

Estimates

Oct 29

reports in 2 days

−$0.14

EPS estimate, this quarter

+1%

estimate change, 90 days

2↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.142

90d

−$0.141

60d

−$0.141

30d

−$0.141

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.14	-$0.18–-$0.09	-0.1%	$2.2K
Next Q	-$0.14	-$0.19–-$0.07	+0.9%	$2.2K
Current FY	-$0.58	-$0.68–-$0.38	+1.0%	$3.7M
Next FY	-$0.62	-$0.93–-$0.40	+5.4%	$12.1M